American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
IsHak, WW, James, DM, Mirocha, J, et al. Patient-reported functioning in major depressive disorder. Ther Adv Chronic Dis. 2016;7(3):160–169.
Beck, A, Crain, AL, Solberg, LI, et al. Severity of depression and magnitude of productivity loss. Ann Fam Med. 2011;9(4):305–311.
4. Dewa, CS, Thompson, AH, Jacobs, P. The association of treatment of depressive episodes and work productivity. Can J Psychiatry. 2011;56(12):743–750.
Jain, G, Roy, A, Harikrishnan, V, Yu, S, Dabbous, O, Lawrence, C. Patient-reported depression severity measured by the PHQ-9 and impact on work productivity: results from a survey of full-time employees in the United States. J Occup Environ Med. 2013;55(3):252–258.
Asami, Y, Goren, A, Okumura, Y. Work productivity loss with depression, diagnosed and undiagnosed, among workers in an Internet-based survey conducted in Japan. J Occup Environ Med. 2015;57(1):105–110.
Uribe, JM, Pinto, DM, Vecino-Ortiz, AI, Gómez-Restrepo, C, Rondón, M. Presenteeism, absenteeism, and lost work productivity among depressive patients from five cities of Colombia. Value Health Reg Issues. 2017;14:15–19.
Evans-Lacko, S, Knapp, M. Global patterns of workplace productivity for people with depression: absenteeism and presenteeism costs across eight diverse countries. Soc Psychiatry Psychiatr Epidemiol. 2016;51(11):1525–1537.
Stonebridge, C, Sutherland, G. Healthy Brains at Work. Estimating the Impact of Workplace Mental Health Benefits and Programs. Ottawa, Canada: The Conference Board of Canada; 1 September 2016.
Lam, RW, McIntosh, D, Wang, J, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 1. Disease burden and principles of care. Can J Psychiatry. 2016;61(9):510–523.
Greer, TL, Kurian, BT, Trivedi, MH. Defining and measuring functional recovery from depression. CNS Drugs. 2010;24(4):267–284.
Langlieb, AM, Guico-Pabia, CJ. Beyond symptomatic improvement: assessing real-world outcomes in patients with major depressive disorder. Prim Care Companion J Clin Psychiatry. 2010;12(2):e1–14.
McIntyre, RS, Lee, Y, Mansur, RB. Treating to target in major depressive disorder: response to remission to functional recovery. CNS Spectr. 2015;20(Suppl 1):20–30.
Sheehan, DV, Nakagome, K, Asami, Y, Pappadoulous, EA, Boucher, M. Restoring function in major depressive disorder: a systematic review. J Affect Disord. 2017;215:299–313.
Buist-Bouwman, MA, Ormel, J, de Graaf, R, et al. Mediators of the association between depression and role functioning. Acta Psychiatr Scand. 2008;118(6):451–458.
Lee, RS, Hermens, DF, Porter, MA, Redoblado-Hodge, MA. A meta-analysis of cognitive deficits in first-episode major depressive disorder. J Affect Disord. 2012;140(2):113–124.
Iosifescu, DV. The relation between mood, cognition and psychosocial functioning in psychiatric disorders. Eur Neuropsychopharmacol. 2012;22(Suppl 3):S499–S504.
Kennedy, N, Foy, K, Sherazi, R, McDonough, M, McKeon, P. Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord. 2007;9(1–2):25–37.
Trivedi, MH, Morris, DW, Wisniewski, SR, et al. Increase in work productivity of depressed individuals with improvement in depressive symptom severity. Am J Psychiatry. 2013;170(6):633–641.
Solomon, DA, Leon, AC, Endicott, J, et al. Psychosocial impairment and recurrence of major depression. Compr Psychiatry. 2004;45(6):423–430.
Hardeveld, F, Spijker, J, De Graaf, R, Nolen, WA, Beekman, AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010;122(3):184–191.
Hasselbalch, BJ, Knorr, U, Kessing, LV. Cognitive impairment in the remitted state of unipolar depressive disorder: a systematic review. J Affect Disord. 2011;134(1–3):20–31.
Goeldner, C, Ballard, TM, Knoflach, F, Wichmann, J, Gatti, S, Umbricht, D. Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target. Neuropharmacology. 2013;64:337–346.
McIntyre, RS, Cha, DS, Soczynska, JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30(6):515–527.
Bortolato, B, Carvalho, AF, McIntyre, RS. Cognitive dysfunction in major depressive disorder: a state-of-the-art clinical review. CNS Neurol Disord Drug Targets. 2014;13(10):1804–1818.
Clark, M, DiBenedetti, D, Perez, V. Cognitive dysfunction and work productivity in major depressive disorder. Expert Rev Pharmacoecon Outcomes Res. 2016;16(4):455–463.
Knight, MJ, Baune, BT. Cognitive dysfunction in major depressive disorder. Curr Opin Psychiatry. 2018;31(1):26–31.
McIntyre, RS, Soczynska, JZ, Woldeyohannes, HO, et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr Psychiatry. 2015;56:279–282.
Garnock-Jones, KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs. 2014;28(9):855–874.
Sanchez, C, Asin, KE, Artigas, F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43–57.
Thase, ME, Mahableshwarkar, AR, Dragheim, M, Loft, H, Vieta, E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 2016;26(6):979–993.
Vieta, E, Loft, H, Florea, I. Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder. Eur Neuropsychopharmacol. 2017;27(9):877–884.
McIntyre, RS, Lophaven, S, Olsen, CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;17(10):1557–1567.
Mahableshwarkar, AR, Zajecka, J, Jacobson, W, Chen, Y, Keefe, RS. A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40(8):2025–2037.
Harrison, JE, Lophaven, S, Olsen, CK. Which cognitive domains are improved by treatment with vortioxetine? Int J Neuropsychopharmacol. 2016; 19(10): pyw054.
McIntyre, RS, Harrison, J, Loft, H, Jacobson, W, Olsen, CK. The effects of vortioxetine on cognitive function in patients with major depressive disorder: a meta-analysis of three randomized controlled trials. Int J Neuropsychopharmacol. 2016; 19(10):pyw055.
McIntyre, RS, Florea, I, Tonnoir, B, Loft, H, Lam, RW, Christensen, MC. Efficacy of vortioxetine on cognitive functioning in working patients with major depressive disorder. J Clin Psychiatry. 2017;78(1):115–121.
Baune, BT, Sluth, LB, Olsen, CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: a short-term, randomized, double-blind, exploratory study. J Affect Disord. 2018;229:421–428.
Florea, I, Loft, H, Danchenko, N, et al. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav. 2017;7(3):e00622.
Chokka, P, Bougie, J, Rampakakis, E, Proulx, J. Assessment in Work productivity and the Relationship with Cognitive symptoms (AtWoRC): primary analysis from a Canadian open-label study of vortioxetine in patients with major depressive disorder (MDD). CNS Spectr. In press. doi: 10.1017/S1092852918000913.
Mueller, R, Hancock, G. Best practices in structural equation modelling. In: Osborne, J, ed. Best Practices in Qualitative Methods. Thousand Oaks, CA: Sage; 2008.
Kline, RB. Principles and Practice of Structural Equation Modeling. New York: Guilford Press; 2011.
Larsen, KG, Haro, JM, Saragoussi, D, Hammer-Helmich, L. Depression severity and cognitive symptoms are independent predictors of functioning in patients with depression. Eur Neuropsychopharmacol. 2017;27(Suppl 4):s806.
Lerner, D, Amick, BC 3rd, Rogers, WH, Malspeis, S, Bungay, K, Cynn, D. The Work Limitations Questionnaire. Med Care. 2001;39(1):72–85.
Kim, JM, Chalem, Y, di Nicola, S, Hong, JP, Won, SH, Milea, D. A cross-sectional study of functional disabilities and perceived cognitive dysfunction in patients with major depressive disorder in South Korea: the PERFORM-K study. Psychiatry Res. 2016;239:353–361.
Hammer-Helmich, L, Haro, JM, Jönsson, B, et al. Functional impairment in patients with major depressive disorder: the 2-year PERFORM study. Neuropsychiatr Dis Treat. 2018;14:239–249.
Saragoussi, D, Christensen, MC, Hammer-Helmich, L, Rive, B, Touya, M, Haro, JM. Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study. Neuropsychiatr Dis Treat. 2018; 14:1339–1350.
Lam, RW, Iverson, GL, Evans, VC, et al. The effects of desvenlafaxine on neurocognitive and work functioning in employed outpatients with major depressive disorder. J Affect Disord. 2016;203:55–61.
Cha, DS, Carmona, NE, Subramaniapillai, M, et al. Cognitive impairment as measured by the THINC-integrated tool (THINC-it): Association with psychosocial function in major depressive disorder. J Affect Disord. 2017;222:14–20.
Srisurapanont, M, Suttajit, S, Eurviriyanukul, K, Varnado, P. Discrepancy between objective and subjective cognition in adults with major depressive disorder. Sci Rep. 2017;7(1):3901.
Fava, M, Mahableshwarkar, AR, Jacobson, W, et al. What is the overlap between subjective and objective cognitive impairments in MDD? Ann Clin Psychiatry. 2018;30(3):176–184.
Jha, MK, Minhajuddin, A, Greer, TL, Carmody, T, Rush, AJ, Trivedi, MH. Early improvement in work productivity predicts future clinical course in depressed outpatients: findings from the CO-MED trial. Am J Psychiatry. 2016;173(12):1196–1204.
Fava, M, Rush, AJ, Alpert, JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008;165(3):342–351.
Seo, HJ, Jung, YE, Kim, TS, et al. Distinctive clinical characteristics and suicidal tendencies of patients with anxious depression. J Nerv Ment Dis. 2011;199(1):42–48.
Gaspersz, R, Nawijn, L, Lamers, F, Penninx, BWJH. Patients with anxious depression: overview of prevalence, pathophysiology and impact on course and treatment outcome. Curr Opin Psychiatry. 2018;31(1):17–25.
Rush, AJ, Trivedi, MH, Wisniewski, SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
Montgomery, SA, Nielsen, RZ, Poulsen, LH, Häggström, L. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine. Hum Psychopharmacol. 2014;29(5):470–482.
Baldwin, DS, Chrones, L, Florea, I, et al. The safety and tolerability of vortioxetine: analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242–252.
Andresen, R, Caputi, P, Oades, LG. Do clinical outcome measures assess consumer-defined recovery? Psychiatry Res. 2010;177(3):309–317.
IsHak, WW, Mirocha, J, Pi, S, et al. Patient-reported outcomes before and after treatment of major depressive disorder. Dialogues Clin Neurosci. 2014;16(2):171–183.
Slade, M, Longden, E. Empirical evidence about recovery and mental health. BMC Psychiatry. 2015;15:285.
Oliveira-Maia, AJ, Mendonça, C, Pessoa, MJ, Camacho, M, Gago, J. The mental health recovery measure can be used to assess aspects of both customer-based and service-based recovery in the context of severe mental illness. Front Psychol. 2016;7:1679.